AmLactin, a therapeutic skin care brand based in the US, has been acquired by Sandoz, a pharmaceutical company.
Parent company Upsher-Smith Laboratories divested the brand for an undisclosed amount in a deal that was managed by Piper Jaffray & Company.
As AmLactin’s new owner, Sandoz aims to continue delivering high value, high quality generics and novel therapies to customers with “even greater precision”.
AmLactin’s range includes products for skin based on alpha hydroxy therapy.
Formulas contain three times the concentration of AHA lactic acid compared with other top selling therapeutic moisturisers, according to the brand.
Products include: Foot Repair, Ultra Smoothing, Rapid Relief and Daily Moisturizing Body Lotion.
